Stockwinners Market Radar for December 26, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EST NXU Inc. trading halted, news pending

18:31 EST Applied Materials exec sells $3.77M in common stock - In a regulatory filing, Applied Materials disclosed that its CTO Omkaram Nalamasu sold 23.2K shares of common stock on December 22nd in a total transaction size of $3.77M.

17:52 EST Syros Pharmaceuticals director buys $4.0M in common stock - In a regulatory filing, Syros Pharmaceuticals disclosed that its director Srinivas Akkaraju bought 905K shares of common stock on December 21st in a total transaction size of $4.0M.

17:16 EST Altisource Asset Management names William C. Erbey as CEO - In a regulatory filing, the company states: "On December 21, 2023, Altisource Asset Management announced that William C. Erbey as the new Chief Executive Officer of the Company. In addition, the Board of Directors of the Company has appointed Mr. Erbey as its Chairman effective as of December 21, 2023. The Company has agreed to pay Mr. Erbey a base salary of $50,000 per year for his service as Chief Executive Officer. There are no other forms of compensation granted at this time."

17:02 EST Bit Digital expects to double Bitcoin mining operations fleet in 2024 - Bit Digital announced that the company targets doubling its operating fleet in its Bitcoin mining operations, to approximately 6.0 EH/s, during 2024.

16:50 EST Amazon gets FDA letter on potentially harmful active pharmaceutical ingredients - Amazon.com receives letter from the FDA, stating: "This letter concerns your firm's distribution of products that violate the Federal Food, Drug, and Cosmetic Act. The United States Food and Drug Administration purchased on your website, www.amazon.com, products that are labeled as energy enhancing supplements or food, but laboratory analyses confirmed that they contained undeclared and potentially harmful active pharmaceutical ingredients. As discussed further below, your firm is responsible for introducing or delivering for introduction into interstate commerce products that are unapproved new drugs under section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Furthermore, the products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. 352. As explained further below, introducing or delivering these products for introduction into interstate commerce is prohibited under sections 301(a), 301(d), and 505(a) of the FD&C Act, 21 U.S.C. 331(a), 331(d), and 355(a). Your firm is also responsible for introducing or delivering for introduction into interstate commerce a food that is prohibited under section 301(ll) of the FD&C Act, 21 U.S.C. 331(ll)." Reference Link

16:35 EST Ellington Financial estimates book value per share $14.06 as of November 30 - Ellington Financial announced its estimated book value per share of common stock of $14.06 as of November 30. This estimate includes the effects of both the previously announced monthly dividend of 15c per share of common stock, payable on December 26, to holders of record on November 30, 2023, with an ex-dividend date of November 29; as well as the previously announced interim monthly dividend of 6c per share of common stock, payable on December 13 to holders of record on December 8, with an ex-dividend date of December 7.

16:32 EST Intuitive Machines enters into strategic partnership with Boryung Corporation - Intuitive Machines is pleased to announce a strategic partnership with the South Korean firm, Boryung Corporation. This partnership brings the American and South Korean commercial companies closer together in cooperation for space exploration endeavors. Boryung, South Korea's leading healthcare investment company, has focused on investing in critical infrastructure and in new research and development opportunities in space and beyond to expand this capability.

16:31 EST Cenntro Electric regains compliance with Nasdaq minimum bid price - Cenntro Electric announced that on December 22, 2023, the Company received written notice from The Nasdaq Stock Market LLC that for the ten consecutive business days from December 8, 2023, to December 21, 2023, the closing bid price of the Company's common stock has been at $1.00 per share or greater.

16:23 EST Regeneron VP Fenimore sells $1.6M in company shares - VP of Regeneron Pharmaceuticals, Christopher Fenimore, disclosed the sale of 1,930 shares of company stock at $844.30 per share between December 21 and December 22, for a total transaction amount of $1,629,502.

16:10 EST SomaLogic corrects 'Madryn Asset Management's misleading disclosure' - SomaLogic (SLGC) issued the following statement in response to a press release issued by Madryn Asset Management on December 26, regarding the pending merger with Standard BioTools (LAB) On Christmas Eve: "Madryn resorted to manufacturing rumors of a third party's interest in SomaLogic as its latest attempt to stand in the way of a Board-approved transaction. Madryn is using desperate tactics and misleading information in a last-ditch effort to undermine confidence in SomaLogic's thorough strategic process and interfere with the resulting value-maximizing transaction between SomaLogic and Standard BioTools.Madryn did not publish the response email from Adam Schechter, Chairman and CEO of LabCorp (LH), which makes clear there is no substance to Madryn's claims. Since the announcement of its pending merger with Standard BioTools, SomaLogic has not received any indication of interest or proposal from LabCorp or any other party with respect to a potential alternative transaction. The correspondence that occurred on Christmas Eve between Avinash Amin, Managing Director at Madryn, Adam Taich, SomaLogic's Interim CEO, and Mr. Schechter and Garheng Kong, Lead Independent Director of LabCorp is laid out below.At 9:53 a.m. ET on Christmas Eve, Mr. Amin sent an email to Mr. Taich, copying Messrs. Schechter and Kong, claiming that LabCorp was "interested in exploring strategic opportunities with SomaLogic." Following Mr. Amin's email, SomaLogic did not receive correspondence in response from LabCorp."

16:08 EST Yoshitsu receives noncompliance notification from Nasdaq - Yoshitsu announced that the company received a written notification letter from Nasdaq notifying the company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq.

16:04 EST Coherus Biosciences announces FDA approval of UDENYCA ONBODY - Coherus BioSciences announced that the FDA approved UDENYCA ONBODY, the company's on-body injector presentation of UDENYCA, a pegfilgrastim biosimilar administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia. The approval of UDENYCA ONBODY was supported by a comprehensive analytical and clinical data package, including pharmacokinetic (PK) and pharmacodynamic bioequivalence data as well as adhesive performance and tolerability data. Commercial availability of UDENYCA ONBODY is planned for the first quarter of 2024.

13:33 EST Chavant Capital Acquisition Corp trading halted, volatility trading pause

12:00 EST EG Acquisition falls -9.6% - EG Acquisition is down -9.6%, or -$1.03 to $9.74.

12:00 EST Cooper-Standard rises 9.7% - Cooper-Standard is up 9.7%, or $1.82 to $20.52.

12:00 EST Wheels Up rises 30.6% - Wheels Up is up 30.6%, or 97c to $4.14.

10:17 EST Parts Id Inc trading halted, news pending

10:00 EST Center Trust falls -5.8% - Center Trust is down -5.8%, or -$1.46 to $23.76.

10:00 EST BIT Mining falls -14.0% - BIT Mining is down -14.0%, or -90c to $5.51.

10:00 EST Nio rises 6.6% - Nio is up 6.6%, or 56c to $8.97.

09:47 EST Daily S&P Biotech Bear 3x Shares falls -5.4% - Daily S&P Biotech Bear 3x Shares is down -5.4%, or -55c to $9.71.

09:47 EST ZIM Integrated falls -7.6% - ZIM Integrated is down -7.6%, or -88c to $10.70.

09:47 EST ClearBridge Energy rises 5.4% - ClearBridge Energy is up 5.4%, or $1.82 to $35.55.

09:44 EST Knightscope announces deployment of two K1 towers in Los Angeles - Knightscope announces the deployment of two new K1 Towers in Los Angeles, CA through a 50-year old real estate development company.

09:40 EST Anghami reports preliminary Q3 subscriber growth of 17% y/y - Anghami announced preliminary results for its third quarter 2023 performance. The company delivered strong results in Q3 2023 compared to Q3 2022. Additionally, the company shared a host of major strategic and operational updates: Subscribers grew 17% Y/Y reaching 1.73M, as of September 30, 2023; Adjusted Revenue grew 8% Y/Y to $30M for the 9 months ending September 30, 2023; Gross Profit Margin for the 9 months ending September 30, 2023, increased to 22%, a significant improvement compared to 12% in the comparable period of 2022; Anghami secured a $5M strategic investment from SRMG at a valuation of $2.5 per share, aimed at further accelerating growth and leveraging both parties' resources and expertise in technology, innovation, and content. Anghami signed a milestone transaction in which OSN Group will contribute its video streaming platform and will invest up to $50M in cash in Anghami:. The investment values Anghami at $3.65 per share and is set to reshape the landscape of music and video streaming in MENA. Amr Diab's highly anticipated "Makanak" album to debut exclusively on Anghami on December 28, 2023, accompanied by a Live Concert Tour.

09:38 EST Inspira Technologies announces 95% accuracy results for HYLA Blood Sensor - Inspira Technologies OXY announced a significant advancement in its sensor technology by its team of experts. This breakthrough, in achieving 95% accuracy compared to standard blood gas analyzers, brings continuous and real-time blood monitoring capabilities compared to traditional blood gas analyzer systems used in hospitals that typically require intermittent blood draws. This advancement signals Inspira's potential entry into the disposables market. The development of the first HYLA variant, key to this advancement, marks a significant step towards its submission under a 510(k) pathway with the U.S. Food & Drug Administration, which is expected in the second half of 2024. This sensor technology is designed to be integrated with the Company's INSPIRA ART100 and was submitted to the FDA in September 2023, with clearance anticipated in the first half of 2024. Dagi Ben-Noon, CEO of Inspira Technologies, commented: "With our sensor technology, we are not only enriching our INSPIRA ART device line but also forging a path into the disposables market, setting the stage for groundbreaking developments in healthcare."

09:37 EST U.S. Trade Representative declines to reverse Apple Watch patent ruling - The Office of the United States Trade Representative said in a statement: "On October 26, 2023, the U.S. International Trade Commission found that Apple, Inc. (AAPL) infringed two patents owned by Masimo Corporation (MASI) and Cercacor Laboratories, Inc, both based in the United States. Since 2005, the Office of the United States Trade Representative has been delegated the President's authority under Section 337 of the Trade Act of 1930 to review the ITC's decision for a 60-day period. After careful consultations, Ambassador Tai decided not to reverse the ITC's determination and the ITC's decision became final on December 26, 2023."

09:35 EST U.S. Trade Representative declines reverse Apple Watch patent ruling - The Office of the United States Trade Representative said in a statement: "On October 26, 2023, the U.S. International Trade Commission found that Apple, Inc. (AAPL) infringed two patents owned by Masimo Corporation (MASI) and Cercacor Laboratories, Inc, both based in the United States. Since 2005, the Office of the United States Trade Representative has been delegated the President's authority under Section 337 of the Trade Act of 1930 to review the ITC's decision for a 60-day period. After careful consultations, Ambassador Tai decided not to reverse the ITC's determination and the ITC's decision became final on December 26, 2023."

09:34 EST Global Gas Corp trading halted, volatility trading pause

09:32 EST VERB's MARKET.live adds 20 more retailers to social shopping platform - Verb Technology Company announces twenty more dynamic new brands have joined the MARKET.live platform. The recent completion of the Company's tech integrations with the ecommerce solutions powering thousands of vendors' existing ecommerce stores are continuing to drive demand from retailers to create new and additional distribution channels and affiliate relationships through MARKET.live.

09:28 EST Ainos initiates second phase of co-development of VOC sensing platform - Ainos announced that it is initiating the second phase of co-development of a volatile organic compound, or VOC, sensing platform, powered by AI Nose technology, in collaboration with Nisshinbo Micro Devices and Taiwan Inabata. The parties aim to finalize the prototype in the third quarter of 2024 and subsequently prepare for mass production.

09:25 EST Sunrise New Energy announces NIPO approval for invention patent - Sunrise New Energy announced that its subsidiary, Sunrise New Energy Materials, has received preliminary approval from the National Intellectual Property Office for its invention patent titled "Fiber-Structured Titanium-Doped Amorphous Carbon Coated Silver Hard Carbon Composite Material and the Preparation Method." The official document number is 2023121501155630. This invention pertains to the field of sodium-ion battery material preparation and introduces a fiber-structured titanium-doped amorphous carbon coated silver hard carbon composite material and its preparation method. Hard carbon, as the main material for the anode of sodium-ion batteries, has become the preferred material due to its wide availability, low cost, and simple preparation process. However, it has limitations such as low specific capacity, low initial efficiency, and deviation in power performance. This invention overcomes the aforementioned drawbacks. The hard carbon composite material of this invention exhibits a core-shell structure, with the inner core composed of silver-doped hard carbon material and the outer shell composed of titanium-doped amorphous carbon. This design enhances the initial efficiency, cycling performance, and rate capability of the anode materials.

09:18 EST DayDayCook enters agreement to acquire Yai's Thai, terms not disclosed - DDC Enterprise has entered into an agreement to acquire Yai's Thai, a Thai American food brand. The acquisition will significantly expand DayDayCook's U.S. footprint and will be financed through a combination of both cash and stock. Yai's Thai is a leading Thai American food brand, with anticipated revenues of $8M-$10M in 2023. The company's focus on high quality, real food ingredients has resulted in rapid growth in the ready-to-eat market with significant new innovations and continued growth expected in 2024. Yai's products are currently sold through over 4,500 stores nationwide including Costco, Whole Foods Market, Safeway, Sprouts, and Kroger. The acquisition is subject to customary closing conditions and is expected to be completed by year end.

09:06 EST FedEx announces $1B accelerated share repurchase program - FedEx announced that it has entered into an accelerated share repurchase agreement with Mizuho Markets to repurchase $1B of FedEx's common stock as part of the company's previously announced share repurchase program. Under the terms of the ASR agreement, FedEx will pay $1B to Mizuho and receive an initial share delivery of approximately 3.2M shares on December 28, with the remainder of the shares, if any, to be delivered no later than February 29, 2024. The total number of shares purchased by FedEx pursuant to the ASR agreement will be based on an average of the volume-weighted average prices of FedEx's common stock during the term of the ASR agreement, less a discount.

09:04 EST Ainos, Nisshinbo Micro Devices, Inabata initiate Phase 2 of VOC codevelopment - Ainos is initiating the second phase of co-development of a volatile organic compound sensing platform, powered by AI Nose technology, in collaboration with Nisshinbo Micro Devices and Taiwan Inabata Sangyo. The parties aim to finalize the prototype in the third quarter of 2024 and subsequently prepare for mass production. In the second phase, the parties plan to finalize the platform's functionality, specifications, and market positioning for the platform. In addition, the parties will also focus on developing the solution's key hardware and software aspects, including manufacturing, form factor, user interface, and safety requirements. Under the co-development, Ainos and NISD will co-develop a VOC sensing platform that leverages Ainos' digital nose intellectual properties, the AI Nose platform. The co-developed platform is intended to be used in a variety of applications including telehealth, automotive, industrial, and environmental safety. Inabata will provide business logistics for the program and liaise between Ainos and NISD. The Parties have a shared vision for the future of VOC sensing technology across a variety of applications, including telehealth, automotive, industrial, and environmental safety. To achieve this vision, the Parties have committed to collaborating on the development of innovative technologies by leveraging Ainos' cutting-edge artificial intelligence algorithm and digital nose technologies. These technologies have been developed over the past decade, and are protected by over 50 active and pending patents. By combining their expertise and resources, the Parties aim to create a new standard in VOC sensing and analysis, utilizing Ainos' deep-learning algorithm and cloud-based big data analysis to provide unparalleled accuracy and insight.

09:02 EST Mullen Automotive delivers 63 additional Class 3 vehicles to Randy Marion - Mullen Automotive announces 63 additional Class 3 vehicles have been delivered to Randy Marion Automotive Group with the Company invoicing RMA for $3,969,000. To-date, The Company has delivered 121 Mullen THREEs to RMA for a total of $7,623,000. The Company is on track to deliver 150 Mullen THREEs by EOY 2023. In total, Randy Marion has committed to 1,000 Class 3 vehicles for a total of $63 million with the majority of the vehicles to be delivered in calendar year 2024. As previously reported, Class 3 production at the Tunica, Mississippi, facility is planned for 150 vehicles for 2023, with total capacity for Class 3 planned at 3,000 vehicles annually per shift. Mullen THREE production is based out of Tunica, which is home to Mullen's commercial vehicle assembly for both the Mullen ONE, Class 1 EV cargo van, and the Class 3 EV cab chassis trucks. Mullen began first deliveries of the Mullen THREE to Randy Marion on Sept. 28, 2023. Randy Marion received its North Carolina license to retail Mullen's commercial EVs on Nov. 16, 2023, opening the ability of the dealership to conduct sales to customers.

09:01 EST FedEx initiates $1B accelerated share repurchase program - FedEx announced that it has entered into an accelerated share repurchase agreement with Mizuho Markets Americas to repurchase $1.0 billion of FedEx's common stock as part of the company's previously announced share repurchase program. Under the terms of the ASR agreement, FedEx will pay $1.0 billion to Mizuho and receive an initial share delivery of approximately 3.2 million shares on December 28, 2023, with the remainder of the shares, if any, to be delivered no later than February 29, 2024. The total number of shares purchased by FedEx pursuant to the ASR agreement will be based on an average of the volume-weighted average prices of FedEx's common stock during the term of the ASR agreement, less a discount.

08:53 EST Marathon Bancorp adopts buyback for up to 5% of outstanding stock

08:34 EST Adit EdTech Acquisition Cor trading halted, news pending

08:32 EST Atreca announces asset purchase agreement for sale of assets to Immunome - Atreca (BCEL) entered into a definitive asset purchase agreement with Immunome (IMNM) to sell a collection of antibody-related assets and materials. Under the terms of the agreement, Immunome would pay Atreca up to $12.5 million, consisting of a $5.5 million upfront payment and up to $7.0 million in clinical development milestones. The asset sale will require approval from Atreca stockholders holding at least a majority of the outstanding shares of Atreca's Class A common stock entitled to vote. A stockholder vote will be sought by proxy solicitation which will include a plan of dissolution calling for the liquidation of any remaining assets, satisfying or making reasonable provisions for any remaining obligations, and making distributions to our stockholders of available proceeds, if any. The board of directors of Atreca intends to seek to distribute remaining funds to our stockholders as quickly as possible, as permitted by law and the plan of dissolution.

08:30 EST Diodes announces promotion of Yu to President - Diodes announced that as part of a multi-year CEO succession plan its board of directors has approved the promotion of Gary Yu to President effective January 2, 2024. Dr. Keh-Shew Lu will continue to serve as Chairman and CEO until at least May 31, 2027, which is consistent with his current employment agreement. Yu joined Diodes in 2008 and currently serves as Chief Operating Officer, a position he was appointed to in February 2023.

08:25 EST Atreca trading halted, news pending

08:11 EST CVRx receives FDA approval for expanded labeling of Barostim - CVRx announced that the FDA has approved revised Instructions For Use - IFU - for Barostim incorporating key long-term clinical data from the BeAT-HF randomized clinical trial. The revised Clinical Summary section of the IFU now includes the primary endpoint results, the 6, 12 and 24 month symptomatic data, the win ratio, and the all-cause mortality data. The Clinical Summary concludes: "In summary, the primary safety endpoint in the Pre-Market Phase was previously met and confirmed in the Post-Market Phase...". The company's estimate of the U.S. annual market opportunity for Barostim has been revised to $2.2 B, or 76,000 new patients, as compared to earlier estimate of $1.4B, or 55,000 new patients, representing increases of approximately 60% and 38%, respectively.

08:07 EST electroCore granted two new U.S. patents - electroCore has received patent issue notifications from the USPTO. The two patents were issued on December 26, 2023, and relate to electroCore's non-invasive vagus nerve stimulation - nVNS - technology: one patent relates to systems and methods for treating medical conditions that include delivering an nVNS therapy regimen, detecting a heart rate variability of the patient, and comparing the HRV with data related to parameters of the therapy regimen. The other patent relates to a medical device that includes a signal generator for applying electrical impulses to the patient for a period of time, wherein the device is configured to deactivate upon a first occurrence of a specific number of single doses being applied to the patient or a specific time elapsing after the first dose is applied.

08:06 EST Bionano Genomics announces publication comparing OGM to CMA and KT - Bionano Genomics announced a publication covering the largest independent prospective prenatal study comparing optical genome mapping - OGM - to a combined workflow of chromosomal microarray analysis - CMA - and karyotyping - KT -. The study highlighted OGM's high analytical concordance with the combined workflow of CMA and KT, and its ability to detect novel pathogenic structural variants missed by those methods. The study also highlighted OGM's potential to provide additional information about SVs and copy number variants - CNVs - compared to CMA and KT. The study reported that OGM demonstrated robust performance across multiple technical and analytical metrics when compared to CMA and KT. OGM also revealed the location and orientation of duplication segments, refined breakpoints of SVs and identified specific repeat contraction disorders that were not detected by other methods. OGM showed a 97.4% sensitivity, 100% specificity, 100% positive predictive value and 99.4% negative predictive value for detecting SVs reported with KT and CMA. OGM identified several additional SVs not detected by CMA and KT and defined location and orientation for eight CNVs, which may help researchers interpret the effect of CNVs more precisely. The study authors concluded that OGM has the potential to serve as a first-tier cytogenetic method for prenatal analysis due to its ability to identify the majority of pathogenic SVs in a single assay. Bionano offers OGM solutions for applications across basic, translational and clinical research.

08:04 EST Adit EdTech Acquisition to voluntarily delist from NYSE American - Adit EdTech Acquisition intends to voluntarily de-list its common stock, units and warrants from The NYSE American. ADEX provided notice of the voluntary de-listing to the NYSE American on December 26, 2023, following indications from NYSE American that NYSE American would decline to approve a listing of the post-closing company, and ADEX intends to timely file a Form 25 with the Securities and Exchange Commission to effect the de-listing. It is anticipated that the de-listing will become effective on or about January 15, 2024. ADEX's decision to voluntarily de-list from the NYSE American was motivated by indications from NYSE American that NYSE American would decline to approve a listing of the post-closing company, ADEX's applications to list its common stock and warrants on securities exchanges in the U.S. and Canada and ADEX's expectations that its common stock and warrants will be listed on an exchange in Canada and the U.S. following the closing of its business combination with Griid Holdco LLC. Following the de-listing, ADEX intends to continue to file the same types of periodic reports and other information it currently files with the U.S. Securities and Exchange Commission.

08:03 EST SCWorx, American Environmental Partners enter reverse merger agreement - American Environmental Partners has signed a definitive agreement and plan of merger on Dec. 21, 2023 with SCWorx Corp. Upon completion of the transaction and approval of the business combination listing application by Nasdaq, the combined company will be named American Environmental Partners, Inc., and the shares will trade on Nasdaq under the ticker symbol "AEPT." The transaction, which was approved by the Boards of Directors of both American Environmental Partners and Worx, is expected to close in the first quarter of calendar year 2024, subject to shareholder approval, regulatory approval and other customary closing conditions. Under the Agreement, Worx has agreed to merge its wholly-owned subsidiary into American Environmental Partners, with American Environmental Partners as the surviving company. As merger consideration for their shares, American Environmental Partners shareholders will receive shares of Worx common stock equal to 83% of the combined Company, on a fully diluted basis, after giving effect to a pre-merger capital raise of up to $6 million by American Environmental Partners, which is a condition to completion of the Agreement. Therefore, Worx shareholders will own 17% of the combined company on a fully-diluted basis after the merger. Upon completion of the Agreement, pursuant to the Merger Agreement, the board of directors of the new Company will consist of five directors, with four designated by American Environmental Partners and one designated by Worx. The Transaction will be considered a "reverse merger" because the shareholders of American Environmental Partners will own more than a majority of the outstanding common stock of the Company following completion of the Proposed Transaction. As such, the Agreement is subject to NASDAQ approving a listing application based on initial inclusion standards. In addition, the closing of the Agreement is subject to satisfaction of the following conditions: satisfactory completion of due diligence review by both parties, American Environmental Partners raising up to $6 Million of equity, and approval by both Worx and American Environmental shareholders, as well as other customary closing conditions.

08:00 EST Nice announces closing of acquisition of LiveVox - NICE (NICE) announced the closing of the acquisition of LiveVox (LVOX). The combination of NICE's market leading platform CXone, with LiveVox's unique AI driven proactive outreach capabilities create the market's only interaction centric platform, the fundamental cornerstone to deliver superior AI driven CX. Barak Eilam, CEO, NICE, said, "The successful completion of this acquisition is a major milestone for NICE as we continue to execute on our strategic vision, further cementing our leadership position. Organizations around the globe are looking to partner with us as they accelerate their CX AI journey, and we are excited to provide them with the most comprehensive platform to help fuel their success. I would like to extend a warm welcome to the talented LiveVox team and take the next step in transforming the CX industry together." There will be no contribution to NICE's revenue and expenses from LiveVox for 2023. The entire LiveVox financial contribution will occur in 2024 and is expected to contribute $142 million to NICE's full-year revenue, for 2024. The acquisition is also expected to be cash flow positive and accretive to NICE's operating income, operating margin and non-GAAP EPS in 2024.

07:55 EST EHang, Shenzhen Bao'an District launch UAM Operation Demonstration Center - EHang Holdings announced the launch of the UAM Operation Demonstration Center at OH Bay, a renowned landmark in Bao'an district, Shenzhen. Following the EHang's strategic partnership with the Shenzhen Bao'an District Government in July, this significant milestone marks another big step forward towards the parties' joint efforts for the launch of aerial sightseeing services for the next phase. This UAM Center was swiftly built within four-month period by Bao'an Transportation Group with the support from the Bao'an District Government. It covers a total area of approximately 4,600 square meters, hosting a comprehensive set of facilities including a bespoke eVTOL vertiport for EHang's passenger-carrying pilotless eVTOL aircraft EH216-S, hangars, a command-and-control center, passenger waiting area, a service center, and various expended essential amenities. At today's launch event for the UAM Center, EH216-S successfully completed its demo flight over OH Bay, which was witnessed by local government officials, regulators, enterprise representatives and citizens. Meanwhile, Bao'an Transportation Group entered into a letter of intent on cooperation with EHang. Two parties will continue to work together to set up an operation demonstration model for passenger-carrying unmanned aerial vehicles and to build a low-altitude economy ecosystem in Shenzhen. Furthermore, Shenzhen Boling Holding Group Co., Ltd., which has purchased 5 units of EH216-S from EHang and plans to purchase additional 95 units in the future, recently established a subsidiary Shenzhen Pengcheng Wings General Aviation, a joint venture with EHang. Pengcheng Wings will be involved in multi-party-cooperation on the low-altitude UAM operations as a flight service operator in Shenzhen.

07:34 EST RayzeBio jumps 99% to $60.96 after Bristol Myers takeover deal - Shares of RayzeBio (RYZB) jumped $30.39, or 99%, to $60.96 in pre-market trading upon the resumption of trading of the stock. Shares had been halted for news pending ahead of the company announcing Bristol Myers Squibb (BMY) will acquire RayzeBio for $62.50 per share in cash.

07:18 EST iBio amends, extends maturity of credit agreement - iBio announced its wholly owned subsidiary, iBio CDMO LLC, and its lender, Woodforest National Bank, have entered into an amendment to the Credit Agreement dated November 1, 2021, extending the Agreement's maturity date from December 31, 2023 to the earlier March 29, 2024, or the acceleration of maturity of the term loan in accordance with the Credit Agreement.

07:15 EST Bristol Myers to acquire RayzeBio for $62.50 per share in cash - Bristol Myers Squibb (BMY) and RayzeBio, Inc. (RYZB) announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors. RayzeBio is a clinical-stage radiopharmaceutical therapeutics company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs. Current pipeline programs are targeting the treatment of solid tumors, including gastroenteropancreatic neuroendocrine tumors, small cell lung cancer, hepatocellular carcinoma and other cancers. There remains a high, unmet need for more effective treatments in solid tumors, and RPTs enable a precision approach to patient treatment. RPTs bind to tumor cells and deliver targeted radiation to induce cancer cell death. Actinium-based RPTs offer potential advantages over currently available RPTs since the high potency and short firing range of the alpha-emitter create the possibility for stronger efficacy and more targeted delivery. The transaction is expected to be treated as a business combination and to be dilutive to Bristol Myers Squibb's non-GAAP diluted earnings per share by approximately $0.13 in 2024. Bristol Myers Squibb expects to finance the acquisition with primarily new debt issuance. Bristol Myers Squibb's cash flows and strong financial profile enable continued commitment to strong investment-grade credit ratings and investment for growth through business development opportunities and distributions to shareholders through ongoing dividends and share repurchases. Under the terms of the merger agreement, Bristol Myers Squibb will promptly commence a tender offer to acquire all of the outstanding shares of RayzeBio common stock at a price of $62.50 per share in an all-cash transaction for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. RayzeBio's Board of Directors unanimously recommends that RayzeBio's shareholders tender their shares in the tender offer. The transaction is expected to close in the first half of 2024, subject to customary closing conditions, including the tender of a majority of the outstanding shares of RayzeBio's common stock and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Following the successful closing of the tender offer, Bristol Myers Squibb will acquire all remaining shares of RayzeBio that are not tendered into the tender offer through a second-step merger at the same price of $62.50 per share.

07:09 EST Milestone Pharmaceuticals to resume trading at 7:30 am ET - Milestone Pharmaceuticals is scheduled to resume trading at 7:30 am ET, with quotation set to resume at 7:25 am ET, according to Nasdaq. Shares had been halted for news pending ahead of the company announcing it had received a Refusal to File letter from the FDA for the New Drug Application for self-administered etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia.

07:08 EST D-Wave stands ready to support new U.S. law on near-term quantum computing - D-Wave Quantum commends U.S. policy makers for including a quantum pilot program focused on near-term quantum computing applications in the National Defense Authorization Act NDAA that was passed by Congress and signed into law by President Biden on December 22. This significant action establishes a program focused on near-term applications development to solve problems facing the Department of Defense DOD including the Armed Forces. This program will test, evaluate, and use quantum and quantum-hybrid applications to address problems facing our defense, military, and national security operations, such as meeting the near-term needs of warfighters, and explicitly calls out consideration to use annealing quantum computing and quantum-hybrid technologies. The new law also calls for building and strengthening relationships between the DOD, academic institutions, small businesses, and non-traditional defense contractors, an important move given the significant quantum innovation driven by small businesses like D-Wave.

07:05 EST Bristol Myers to acquire RayzeBio for $62.50 per share in cash - Bristol Myers Squibb (BMY) and RayzeBio (RYZB) announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1B, or $3.6B net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors. RayzeBio is a clinical-stage radiopharmaceutical therapeutics company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs. Current pipeline programs are targeting the treatment of solid tumors, including gastroenteropancreatic neuroendocrine tumors, small cell lung cancer, hepatocellular carcinoma and other cancers. There remains a high, unmet need for more effective treatments in solid tumors, and RPTs enable a precision approach to patient treatment. RPTs bind to tumor cells and deliver targeted radiation to induce cancer cell death. Actinium-based RPTs offer potential advantages over currently available RPTs since the high potency and short firing range of the alpha-emitter create the possibility for stronger efficacy and more targeted delivery. RayzeBio's portfolio includes: Lead program RYZ101, targeting somatostatin receptor 2 (SSTR2), which is over-expressed in GEP-NETs and extensive stage small cell lung cancer. A Phase 3 clinical trial is currently enrolling patients to evaluate RYZ101 in patients with SSTR-positive GEP-NETs who have previously been treated with lutetium-177 based somatostatin therapies. RayzeBio previously reported the interim results of the Phase 1b portion of the ACTION-1 clinical trial, suggesting encouraging efficacy and tolerability. A Phase 1b clinical trial is also currently enrolling patients to evaluate RYZ101 as a first-line treatment of ES-SCLC in combination with standard-of-care therapy. RYZ801, RayzeBio's novel proprietary peptide targeting glypican-3 for delivery of actinium- based radioactivity for the treatment of hepatocellular carcinoma. RYZ801 is currently in IND-enabling studies. Pipeline also includes an asset targeting CA9, which is expressed in renal cell cancer and is currently in IND-enabling studies. Multiple first-in-class preclinical assets to treat solid tumors. RayzeBio is completing construction of a state-of-the-art in-house manufacturing facility in Indianapolis, Indiana, and GMP drug production is expected to begin in the first half of 2024. The transaction is expected to be treated as a business combination and to be dilutive to Bristol Myers Squibb's non-GAAP diluted earnings per share by approximately $0.13 in 2024. Bristol Myers Squibb expects to finance the acquisition with primarily new debt issuance. Bristol Myers Squibb's cash flows and strong financial profile enable continued commitment to strong investment-grade credit ratings and investment for growth through business development opportunities and distributions to shareholders through ongoing dividends and share repurchases. Under the terms of the merger agreement, Bristol Myers Squibb will promptly commence a tender offer to acquire all of the outstanding shares of RayzeBio common stock at a price of $62.50 per share in an all-cash transaction for a total equity value of approximately $4.1B, or $3.6B net of estimated cash acquired. RayzeBio's Board of Directors unanimously recommends that RayzeBio's shareholders tender their shares in the tender offer. The transaction is expected to close in the first half of 2024, subject to customary closing conditions, including the tender of a majority of the outstanding shares of RayzeBio's common stock and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Following the successful closing of the tender offer, Bristol Myers Squibb will acquire all remaining shares of RayzeBio that are not tendered into the tender offer through a second-step merger at the same price of $62.50 per share.

07:03 EST Bristol Myers to acquire RayzeBio for $62.50 per share in cash

07:00 EST Infosys reports termination of $1.5B AI deal - In a December 23 exchange filing, Infosys said, "This is in continuation to the disclosure made by Infosys vide letter dated September 14, 2023, titled 'Company update' with respect to a Memorandum of Understanding with a global company which was subject to parties entering into a Master Agreement. The global company has now elected to terminate the Memorandum of Understanding and the parties will not be pursuing the Master Agreement." On September 14, the company had said, "Infosys has entered into a Memorandum of Understanding with a global company to provide enhanced digital experiences, along with modernization and business operations services, leveraging Infosys platforms & AI solutions. The total client target spend over 15 years is estimated at $1.5B. This is subject to parties entering into a Master Agreement." Reference Link

06:51 EST PNM Resources announces NMRC approval for battery storage projects - The New Mexico Public Regulation Commission, or NMPRC, approved the application from Public Service Company of New Mexico, wholly-owned subsidiary of PNM Resources, to install 12 megawatts of utility owned distribution-level battery storage to expand the capacity of overloaded feeders at two locations.

06:34 EST PNM Resources to sell 50% ownership interest in NMRD for $115M - PNM Resources has entered into an agreement to sell its 50% ownership interest in its renewable joint venture, New Mexico Renewable Development, or NMRD, to Exus North America Holdings. PNM Resources and American Electric Power, or AEP, which also owns 50% of NMRD, have agreed to sell the NMRD portfolio for approximately $230M subject to true-up adjustments at close. PNM Resources' $115M share of the approximate gross proceeds will support the funding of regulated capital investments. The sale is expected to close in February 2024. The NMRD portfolio includes nine operating solar developments totaling 185 MW and six projects under development with an estimated output of 440 MW. PNM Resources reports the earnings from its 50% ownership as part of the corporate and other segment. The sale is subject to regulatory approval by the Federal Energy Regulatory Commission and New Mexico regulatory approvals associated with one of NMRD's projects. The waiting period for Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired.

06:17 EST Tarena to sell professional education business, terms undisclosed - Tarena announced that it has signed an equity transfer agreement to dispose of all equity interests in the professional education business to a buyer consortium led by Tarena Weishang Technology. Lijuan Han, affiliate of the company's founder and chairman Shaoyun Han, is a member of the buyer consortium and has an interest in the disposal transaction. Kroll, LLC was retained as the independent financial advisor in connection with the disposal transaction. The disposal transaction is expected to close around the end of March 2024.

06:13 EST Huntington completed credit risk transfer of $3B in prime auto loans - Huntington Bancshares on Friday provided a Q4 investor update, which included a completed synthetic credit risk transfer related to $3B in prime auto loans on December 19. The transaction is expected to reduce risk-weighted assets by $2.4B, which risk-weight moving from 100% to 20% on a selected pool of assets, Huntington said. As a result, the bank's common equity tier 1 capital is expected to benefit by 17 basis points. Reference Link

05:30 EST Stratasys up 9% to $14.35 after takeover offer from Nano Dimension

05:23 EST Nanobiotix says LianBio enters NBTXR3 development pact with Johnson & Johnson - Nanobiotix (NBTX) announced that partner LianBio (LIAN) has entered into an agreement with Janssen Pharmaceutica, a Johnson & Johnson (JNJ) company, whereby LianBio has assigned to Janssen LianBio's exclusive rights to develop and commercialize radioenhancer NBTXR3 in China, South Korea, Singapore, and Thailand. This agreement consolidates global development and commercialization rights of NBTXR3 with Janssen; streamlines the global alliance for co-development and registration of the radioenhancer with Nanobiotix; and includes all previously agreed upon economic terms between Nanobiotix and LianBio, including the Nanobiotix entitlement to receive up to an aggregate $220M in potential contingent, development and commercialization milestone payments along with tiered, low double-digit royalties based on net sales of NBTXR3 in Asian territories. Following the deal close, LianBio will support the transition of the asset to Janssen for a period no longer than six months.

04:37 EST Huntington completed credit risk transfer of $3B in primate auto loans - Huntington Bancshares on Friday provided a Q4 investor update, which included a completed synthetic credit risk transfer related to $3B in prime auto loans on December 19. The transaction is expected to reduce risk-weighted assets by $2.4B, which risk-weight moving from 100% to 20% on a selected pool of assets, Huntington said. As a result, the bank's common equity tier 1 capital is expected to benefit by 17 basis points. Reference Link